Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Counter-balanced crossover study (n=13) testing whether perampanel (6 mg oral) pre-treatment blocks IV ketamine antidepressant effects in treatment-resistant depression; outcomes include fMRI connectivity, CMRO2 and clinical scales at 24 hours.
Details
Randomized, double-blind, counter-balanced crossover in individuals with treatment-resistant depression comparing ketamine with perampanel pre-treatment versus ketamine with placebo; primary outcomes are changes in prefrontal functional connectivity and CMRO2 during infusion and at 24 hours.
The study includes a small safety substudy in three healthy subjects; clinical response is assessed with the Hamilton Depression Rating Scale and imaging measures to test whether AMPAR stimulation is necessary for ketamine’s antidepressant effects.